Pfizer in technology licensing deal with Xoma

Share this article:

Drug developer Xoma announced that it has licensed technology to Pfizer that can be used to screen and make antibody products, the Associated Press reported.

Xoma said it will license the technology for an upfront payment of $30 million, along with future royalty and milestone payments.

Xoma also licenses the technology to companies including Merck, Centocor and Alexion Pharmaceuticals. Xoma receives royalties from Genentech for its macular degeneration drug Lucentis because that drug uses its bacterial cell expression technology.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.